Turn Therapeutics Inc. announced that its GX-03 technology, a topical IL36/IL31 inhibitor, has been recognized as one of "Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment" by Patient Care Online Magazine. The company highlighted that GX-03 represents the first topical agent targeting IL-36, a key player in the inflammatory processes of atopic dermatitis, eczema, and psoriasis. Preclinical studies showed GX-03's ability to inhibit several targets, including IL-36 alpha, IL-31, IL-4, and IL-36 gamma. Turn Therapeutics stated that topline data from its lead program in severe eczema will be announced in early 2026. Research results have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-108655), on November 12, 2025, and is solely responsible for the information contained therein.